The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
80 mg daily
5 mg daily
Catholic University of the Sacred Heart
Rome, Italy
RECRUITINGHigh sensitivity C-Reactive Protein
Time frame: 20 days after hospital discharge
Endothelial Progenitor Cells
Time frame: 20 days after hospital discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.